Hybrid Molecules Inhibiting Myeloperoxidase Activity and Serotonin Reuptake: A Possible New Approach of Major Depressive Disorders with Inflammatory Syndrome
Hybrid Molecules Inhibiting Myeloperoxidase Activity and Serotonin Reuptake: A Possible New Approach of Major Depressive Disorders with Inflammatory Syndrome
Publication date :
01 August 2014
Journal title :
Journal of Pharmacy and Pharmacology
ISSN :
0022-3573
Publisher :
Wiley, London, United Kingdom
Research unit :
M136 - Chimie thérapeutique et Pharmacognosie
Research institute :
R550 - Institut des Sciences et Technologies de la Santé
Libby P, etal. Progress and challenges in translating the biology of atherosclerosis. Nature 2011; 473: 317-325.
Holtzheimer PE, Mayberg HS,. Stuck in a rut: rethinking depression and its treatment. Trends Neurosci 2011; 34: 1-9.
Lee S, etal. Depression research: where are we now? Mol Brain 2010; 3: 8.
Sluzewska A, etal. Indicators of immune activation in major depression. Psychiatry Res 1996; 64: 161-167.
Maes M, etal. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 1997; 9: 853-858.
Maes M, etal. Immune disturbances in treatment-resistant depression: modulation by antidepressive treatments. Hum Psychopharmacol Clin Exp 1997; 12: 153-162.
Vaccarino V, etal. Association of major depressive disorder with serum myeloperoxidase and other markers of inflammation: a twin study. Biol Psychiatry 2008; 64: 476-483.
Maes M, etal. Increased plasma peroxides and serum oxidized low density lipoprotein antibodies in major depression: markers that further explain the higher incidence of neurodegeneration and coronary artery disease. J Affect Disord 2010; 125: 287-294.
Wozniak G, etal. Serotonin reuptake inhibitor antidepressants (SSRIs) against atherosclerosis. Med Sci Monit 2011; 17: RA205-RA214.
Uno K, Nicholls SJ,. Biomarkers of inflammation and oxidative stress in atherosclerosis. Biomark Med 2010; 4: 361-373.
Huo Y, Ley FK,. Role of platelets in the development of atherosclerosis. Trends Cardiovasc Med 2004; 14: 18-22.
Angiolillo DJ, etal. Basic principles of platelet biology and clinical implications. Circ J 2010; 74: 597-607.
Tseng Y-L, etal. A selective serotonin reuptake inhibitor, citalopram, inhibits collagen-induced platelet aggregation and activation. Thromb Res 2010; 126: 517-523.
Bampalis VG, etal. Fluoxetine inhibition of 5-HT-potentiated platelet aggregation in whole blood. Thromb Haemost 2010; 104: 1272-1274.
Galan AM, etal. Platelets and blood cells. Thromb Haemost 2009; 102: 511-519.
Atar D, etal. Antiplatelet properties of escitalopram in patients with the metabolic syndrome: a dose-ranging in vitro study. Neuropsychopharmacology 2007; 32: 2369-2374.
Serebruany VL, etal. Selective serotonin reuptake inhibitors yield additional antiplatelet protection in patients with congestive heart failure treated with antecedent aspirin. Eur J Heart Fail 2003; 5: 517-521.
Novio S, etal. Effects of fluoxetine on the oxidative status of peripheral blood leucocytes of restraint-stressed mice. Basic Clin Pharmacol Toxicol 2011; 109: 365-371.
Eren I, etal. Protective effects of lamotrigine, aripiprazole and escitalopram on depression-induced oxidative stress in rat brain. Neurochem Res 2007; 32: 1188-1195.
Kumar A, Garg R,. Protective effects of antidepressants against chronic fatigue syndrome-induced behavioral changes and biochemical alterations. Fundam Clin Pharmacol 2009; 23: 89-95.
Chung YC, etal. Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease. J Immunol 2010; 185: 1230-1237.
Crino PB, etal. Neurotoxic effects of partially oxidized serotonin: tryptamine-4,5-dione. Brain Res 1989; 504: 247-257.
Ximenes VF, etal. Serotonin as a physiological substrate for myeloperoxidase and its superoxide-dependent oxidation to cytotoxic tryptamine-4,5-dione. Biochem J 2009; 425: 285-293.
Suchet K, etal. Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep 2003; 8: 365-370.
For reviews on the subject see:, Maia RDC, Fraga CAM,. Discovery of dual chemotherapy drug candidates designed by molecular hybridization. Curr Enzyme Inhib 2010; 6: 171-182
Meunier B,. Hybrid molecules with a dual mode of action: dream or reality? Acc Chem Res 2008; 41: 69-77
Richards J,. Patent issues relating to hybrid drugs. Expert Opin Ther Pat 2008; 18: 1191-1194.
Van der Steen JW,. Assessing overmedication: biology, philosophy and common sense. Acta Biotheor 2003; 51: 151-171.
Soubhye J, etal. Structure-based design, synthesis, and pharmacological evaluation of 3-(Aminoalkyl)-5-fluoroindoles as myeloperoxidase inhibitors. J Med Chem 2010; 53: 8747-8759.
Soubhye J, etal. Design, synthesis, and structure-activity relationship studies of novel 3-alkylindole derivatives as selective and highly potent myeloperoxidase inhibitors. J Med Chem 2013; 56: 3943-3958.
Schmitz WD, etal. Homotryptamines as potent and selective serotonin reuptake inhibitors (SSRIs). Bioorg Med Chem Lett 2005; 15: 1619-1621.
Mattson RJ, etal. Conformationally restricted homotryptamines. Indole cyclopropylmethylamines as selective serotonin reuptake inhibitors. J Med Chem 2005; 48: 6023-6034.
King HD, etal. Conformationally restricted homotryptamines. Part 7: 3-cis-(3-aminocyclopentyl)indoles as potent selective serotonin reuptake inhibitors. J Med Chem 2010; 53: 7564-7572.
Kristensen AS, etal. Mutational scanning of the human serotonin transporter reveals fast translocating serotonin transporter mutants. Eur J Neurosci 2004; 19: 1513-1523.
Larsen MB, etal. The chicken serotonin transporter discriminates between serotonin-selective reuptake inhibitors: a species-scanning mutagenesis study. J Biol Chem 2004; 279: 42147-42156.
Altschul SF, etal. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 1997; 25: 3389-3402.
Eswar N, etal. Comparative protein structure modeling with MODELLER. In: Current Protocols in Bioinformatics. Hoboken, NJ: John Wiley & Sons Inc., 2006: 1-30. Supplement 15.
Pei J, Grishin N,. PROMALS: towards accurate multiple sequence alignments of distantly related proteins. Bioinformatics 2007; 23: 802-808.
Adkins EM, etal. Interactions of tryptamine derivatives with serotonin transporter species variants implicate transmembrane domain I in substrate recognition. Mol Pharmacol 2001; 59: 514-523.
Sherman W, etal. Novel procedure for modeling ligand/receptor induced fit effects. J Med Chem 2006; 49: 534-553.
Wang H, etal. Structural basis for action by diverse antidepressants on biogenic amine transporters. Nature 2013; 503: 141-145.
Penmatsa A, etal. X-ray structure of dopamine transporter elucidates antidepressant mechanism. Nature 2013; 503: 85-90.
Celik L, etal. Binding of serotonin to the human serotonin transporter. Molecular modeling and experimental validation. J Am Chem Soc 2008; 130: 3853-3865.
Jantschko W, etal. Exploitation of the unusual thermodynamic properties of human myeloperoxidase in inhibitor design. Biochem Pharmacol 2005; 69: 1149-1157.
Malle E, etal. Myeloperoxidase: a target for new drug development? Br J Pharmacol 2007; 152: 838-854.
Segura M, etal. Synthesis of the major metabolites of paroxetine. Bioorg Chem 2003; 31: 248-258.
Ward J, etal. Mechanistic characterization of a 2-thioxanthine myeloperoxidase inhibitor and selectivity assessment utilizing click chemistry-activity-based protein profiling. Biochemistry 2013; 52: 9187-9201.
Tiden AK, etal. 2-thioxanthines are mechanism-based inactivators of myeloperoxidase that block oxidative stress during inflammation. J Biol Chem 2011; 286: 37578-37589.
Kelvin AS, Håkansson S,. Comparative acute toxicity of paroxetine and other antidepressants. Acta Psychiatr Scand Suppl 1989; 80: 31-33.
Ryan PM, etal. The toxicity profile of a single dose of paroxetine: an alternative approach to acute toxicity testing in the rat. Pharmacol Toxicol 2001; 88: 59-66.
Franck T, etal. A new easy method for specific measurement of active myeloperoxidase in human biological fluids and tissue extracts. Talanta 2009; 80: 723-729.
Delporte C, etal. Simultaneous measurement of protein-bound 3-chlorotyrosine and homocitrulline by LC-MS/MS after hydrolysis assisted by microwave: application to the study of myeloperoxidase activity during hemodialysis. Talanta 2012; 99: 603-609.
Parry MF, etal. Myeloperoxidase deficiency: prevalence and clinical significance. Ann Intern Med 1981; 95: 293-301.
